Dr. Mark Emberton presented “Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Standard of Care” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: prostate cancer, focal therapy, lesion
How to cite: Emberton, Mark. “Focal Therapy for Men with Intermediate Risk Prostate Cancer and a Solitary Lesion Should Be the Standard of Care” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2025. https://grandroundsinurology.com/focal-therapy-men-intermediate-risk-prostate-cancer-solitary-lesion-standard-care.
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organised by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Mark Emberton, MD, FRCS, is Dean for the Faculty of Medical Sciences, and Professor of Interventional Oncology for the Division of Surgery and Interventional Science at University College London in London, England. He is also an Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England, and UCL Partners' Pathway Director for urological oncology for London Cancer. Professor Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer. He specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials, and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.
